|
|
Volumn 61, Issue 23, 2004, Pages
|
|
Ximelagatran data fail to impress FDA
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
PLACEBO;
THROMBIN INHIBITOR;
WARFARIN;
XIMELAGATRAN;
AZETIDINE DERIVATIVE;
BENZYLAMINE DERIVATIVE;
CLINICAL TRIAL;
DEEP VEIN THROMBOSIS;
DRUG APPROVAL;
DRUG EFFICACY;
FOOD AND DRUG ADMINISTRATION;
HEART ATRIUM FIBRILLATION;
HUMAN;
LIVER FAILURE;
LIVER TOXICITY;
LUNG EMBOLISM;
MEDICAL ETHICS;
NOTE;
PRIORITY JOURNAL;
STROKE;
TOTAL KNEE REPLACEMENT;
VENOUS THROMBOEMBOLISM;
ADVISORY COMMITTEE;
ARTICLE;
CEREBROVASCULAR ACCIDENT;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
EMBOLISM;
RANDOMIZED CONTROLLED TRIAL;
TOXIC HEPATITIS;
UNITED STATES;
VEIN THROMBOSIS;
ADVISORY COMMITTEES;
ANTICOAGULANTS;
ATRIAL FIBRILLATION;
AZETIDINES;
BENZYLAMINES;
CEREBROVASCULAR ACCIDENT;
DRUG APPROVAL;
EMBOLISM;
HEPATITIS, TOXIC;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
VENOUS THROMBOSIS;
|
|
EID: 15544368754
PISSN: 10792082
EISSN: None
Source Type: Journal
DOI: 10.1093/ajhp/61.23.2472 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|